Alpha 2.0
Login Register
» Authors » Han van den Bosch

Han van den Bosch

Explore the profile of Han van den Bosch including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 13
Citations 223
Followers 0
Related Specialties
Allergy & Immunology
Pharmacology
Microbiology
Top 10 Co-Authors
Jacco G M Heldens
Wim Jiskoot
J Theo M Voeten
Enrico Mastrobattista
Niels Hagenaars
Larisa Rudenko
Harrie L Glansbeek
Li-Mei Chen
Ruben O Donis
Irina Isakova-Sivak
Published In
Vaccine
J Control Release
J Gen Virol
J Infect Dis
Pharm Res
Affiliations
Soon will be listed here.
Recent Articles
1.
Safety and immunogenicity in man of a cell culture derived trivalent live attenuated seasonal influenza vaccine: a Phase I dose escalating study in healthy volunteers
Heldens J, Hulskotte E, Voeten T, Breedveld B, Verweij P, van Duijnhoven W, et al.
Vaccine . 2014 May; 32(39):5118-24. PMID: 24858566
Live attenuated influenza vaccine (LAIV) offers the promise of inducing a variety of immune responses thereby conferring protection to circulating field strains. LAIVs are based on cold adapted and temperature...
2.
Characterization of reverse genetics-derived cold-adapted master donor virus A/Leningrad/134/17/57 (H2N2) and reassortants with H5N1 surface genes in a mouse model
Isakova-Sivak I, Chen L, Bourgeois M, Matsuoka Y, Voeten J, Heldens J, et al.
Clin Vaccine Immunol . 2014 Mar; 21(5):722-31. PMID: 24648485
Live attenuated influenza vaccines (LAIV) offer significant advantages over subunit or split inactivated vaccines to mitigate an eventual influenza pandemic, including simpler manufacturing processes and more cross-protective immune responses. Using...
3.
A step-by-step approach to study the influence of N-acetylation on the adjuvanticity of N,N,N-trimethyl chitosan (TMC) in an intranasal nanoparticulate influenza virus vaccine
Verheul R, Hagenaars N, van Es T, van Gaal E, de Jong P, Bruijns S, et al.
Eur J Pharm Sci . 2011 Oct; 45(4):467-74. PMID: 22009112
Recently we reported that reacetylation of N,N,N-trimethyl chitosan (TMC) reduced the adjuvant effect of TMC in mice after intranasal (i.n.) administration of whole inactivated influenza virus (WIV) vaccine. The aim...
4.
Comparative immunogenicity and cross-clade protective efficacy of mammalian cell-grown inactivated and live attenuated H5N1 reassortant vaccines in ferrets
Gustin K, Maines T, Belser J, Van Hoeven N, Lu X, Dong L, et al.
J Infect Dis . 2011 Sep; 204(10):1491-9. PMID: 21957153
Continued H5N1 virus infection in humans highlights the need for vaccine strategies that provide cross-clade protection against this rapidly evolving virus. We report a comparative evaluation in ferrets of the...
5.
Live attenuated pandemic influenza vaccine: clinical studies on A/17/California/2009/38 (H1N1) and licensing of the Russian-developed technology to WHO for pandemic influenza preparedness in developing countries
Rudenko L, van den Bosch H, Kiseleva I, Mironov A, Naikhin A, Larionova N, et al.
Vaccine . 2011 Jun; 29 Suppl 1:A40-4. PMID: 21684428
In February 2009, Nobilon granted the World Health Organization (WHO) a non-exclusive licence to develop, register, manufacture, use and sell seasonal a pandemic live attenuated influenza vaccine (LAIV) produced on...
6.
Genetic bases of the temperature-sensitive phenotype of a master donor virus used in live attenuated influenza vaccines: A/Leningrad/134/17/57 (H2N2)
Isakova-Sivak I, Chen L, Matsuoka Y, Voeten J, Kiseleva I, Heldens J, et al.
Virology . 2011 Feb; 412(2):297-305. PMID: 21315402
Trivalent live attenuated influenza vaccines whose type A components are based on cold-adapted A/Leningrad/134/17/57 (H2N2) (caLen17) master donor virus (MDV) have been successfully used in Russia for decades to control...
7.
Master donor viruses A/Leningrad/134/17/57 (H2N2) and B/USSR/60/69 and derived reassortants used in live attenuated influenza vaccine (LAIV) do not display neurovirulent properties in a mouse model
Voeten J, Kiseleva I, Glansbeek H, Basten S, Drieszen-van der Cruijsen S, Rudenko L, et al.
Arch Virol . 2010 Jun; 155(9):1391-9. PMID: 20532926
Demonstration of the absence of neurovirulent properties of reassortant viruses contained in live attenuated influenza vaccine (LAIV) is a regulatory requirement. A mouse model was used to detect neurovirulent properties...
8.
Role of trimethylated chitosan (TMC) in nasal residence time, local distribution and toxicity of an intranasal influenza vaccine
Hagenaars N, Mania M, de Jong P, Que I, Nieuwland R, Slutter B, et al.
J Control Release . 2010 Jan; 144(1):17-24. PMID: 20100528
The nose is a promising immunization site and intranasal (i.n.) vaccination studies with whole inactivated influenza virus (WIV) adjuvanted with N,N,N-trimethylchitosan (TMC-WIV) have shown promising results. In this study, the...
9.
PB2 and PA genes control the expression of the temperature-sensitive phenotype of cold-adapted B/USSR/60/69 influenza master donor virus
Kiseleva I, Voeten J, Teley L, Larionova N, Drieszen-van der Cruijsen S, Basten S, et al.
J Gen Virol . 2009 Dec; 91(Pt 4):931-7. PMID: 20007357
The cold-adapted (ca) and temperature-sensitive (ts) influenza master donor virus (MDV) B/USSR/60/69 was derived from its wild-type parental virus after successive passages in eggs at 32 degrees C and 25...
10.
Relationship between structure and adjuvanticity of N,N,N-trimethyl chitosan (TMC) structural variants in a nasal influenza vaccine
Hagenaars N, Verheul R, Mooren I, de Jong P, Mastrobattista E, Glansbeek H, et al.
J Control Release . 2009 Aug; 140(2):126-33. PMID: 19712713
The aim of this study was to assess the influence of structural properties of N,N,N-trimethyl chitosan (TMC) on its adjuvanticity. Therefore, TMCs with varying degrees of quaternization (DQ, 22-86%), O-methylation...